Complete Portfolio

From neuroscience to oncology, our therapies address serious unmet medical needs.

🧠
Neuroscience

NeuroVex®

Mild Cognitive Impairment

Advanced nootropic therapy designed to support cognitive function in adults 55 and older. NeuroVex® targets multiple neural pathways to enhance memory consolidation, processing speed, and mental clarity.

  • 23% improvement in memory recall (vs. placebo)
  • Neuroprotective properties
  • Once-daily oral formulation
💉
Oncology

OncoShield®

Advanced Solid Tumors

Next-generation checkpoint inhibitor that unleashes the body's immune system against cancer. OncoShield® has received Breakthrough Therapy designation for metastatic melanoma and is being studied in multiple tumor types.

  • 42% objective response rate in melanoma
  • Durable responses lasting 12+ months
  • IV infusion every 3 weeks
🫀
Cardiology

CardioGen®

Hereditary Cardiomyopathy

First-in-class gene therapy for patients with genetic forms of heart failure. CardioGen® delivers a functional copy of the MYBPC3 gene directly to cardiac tissue, addressing the root cause of disease.

  • One-time IV administration
  • 38% improvement in ejection fraction
  • First approved cardiac gene therapy in North America
🦴
Bone Health

OsteoForce®

Severe Osteoporosis

Revolutionary monoclonal antibody that inhibits bone resorption while promoting new bone formation. OsteoForce® offers a once-yearly injection option for patients with severe osteoporosis who have failed other therapies.

  • 14% increase in spine BMD at 12 months
  • 73% reduction in vertebral fractures
  • Once-yearly subcutaneous injection
👁️
Ophthalmology

RetinaGen®

Inherited Retinal Dystrophies

Gene therapy for patients with vision loss caused by mutations in the RPE65 gene. RetinaGen® has restored functional vision in patients who were previously considered untreatable.

  • One-time subretinal administration
  • 93% of patients improved on light sensitivity
  • Durable efficacy through 5 years
🛡️
Immunology

ImmunoVax®

Autoimmune Disorders

Precision immunotherapy that selectively modulates overactive immune responses without broad immunosuppression. Approved for rheumatoid arthritis and under investigation for multiple sclerosis.

  • 68% ACR50 response at 24 weeks
  • Targeted mechanism preserves immune function
  • Monthly subcutaneous injection

For Healthcare Providers

Access prescribing information, clinical data, and patient support resources